Neuberger Berman Group
DFTX

Neuberger Berman Group’s Definium Therapeutics DFTX Stock Holding History

Neuberger Berman Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3M Buy
687,539
+554,170
+416% +$13.7M 0.02% 603
2026
Q1 		$2.52M Buy
+133,369
New +$2.26M ﹤0.01% 1119

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Neuberger Berman Group's DFTX Position: Q2 2026 in Review

Neuberger Berman Group increased its Definium Therapeutics (DFTX) stake by 416% in Q2 2026, buying an estimated $13.7M and bringing the position to 687,539 shares worth $32.3M. The position accounts for 0.02% of the portfolio, ranked #603.

Neuberger Berman Group first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Neuberger Berman Group held 687,539 shares of Definium Therapeutics worth $32.3M as of Q2 2026.
  • Neuberger Berman Group bought 554,170 Definium Therapeutics shares in Q2 2026, an estimated $13.7M.
  • Definium Therapeutics made up 0.02% of Neuberger Berman Group's portfolio in Q2 2026, its #603 holding.
  • Neuberger Berman Group first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.